Medical Maneuvers

Pfizer’s $106.4 billion buyout offer of British pharmaceutical giant AstraZeneca is being largely driven by high US corporate taxes. At yearend 2013, Pfizer had $70 billion of overseas earnings that, if repatriated, would result in huge US taxes. Buying AstraZeneca with the overseas earnings eliminates the tax bill on the $70 billion and moving the merged firm’s headquarters from here to the lightly taxed UK reduces taxes on future earnings.

Share This Post
Facebook Twitter Email

Speak Your Mind


This site uses Akismet to reduce spam. Learn how your comment data is processed.